Observed Signal · Oct 8, 2026 · Market Signal · Source: Galderma · Impact: 2/5
Fall Clinical 2026: Galderma presents new three-year Nemluvio® data showing deep and lasting skin lesion and itch responses in patients with atopic dermatitis aged 12 and older
Galderma's latest press release announces new three-year data for Nemluvio® in atopic dermatitis, presented at Fall Clinical 2026.
Track Galderma Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your free Explorer workspace to monitor these entities.
Connected Companies & Entities
1 Entity mappedRelated Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
EADV 2026: Galderma’s new data show sustained improvements with Nemluvio® (nemolizumab) for up to three years in patients with moderate-to-severe atopic dermatitis
Galderma's latest press release highlights new data presented at EADV 2026 showing sustained improvements with Nemluvio® (nemolizumab) for up to three years in patients with moderate-to-severe atopic dermatitis. Additionally, Galderma has begun trading in the Swiss Market Index, joining Switzerland's leading blue chip companies.
REGENXBIO Presents Positive 3-Year Data for Sura-vec in Diabetic Retinopathy
REGENXBIO Inc. announced positive three-year durability data from the Phase II ALTITUDE study of its investigational gene therapy surabgene lomparvovec (sura-vec, ABBV-RGX-314) for diabetic retinopathy (DR), presented at the Retina Society 59th Annual Scientific Meeting. The data showed that a majority of Dose Level 3 participants with non-proliferative DR (NPDR) achieved a >2-step improvement on the Diabetic Retinopathy Severity Scale (DRSS) at three years after a single, in-office suprachoroidal injection, with no vision-threatening events and no additional treatment for DR. No intraocular inflammation (IOI) was observed with short-course prophylactic topical steroids. These results support the potential of sura-vec as a one-time treatment that could reduce the burden of repeat injections for patients.
Galderma begins trading in the Swiss Market Index, joining Switzerland's leading blue chip companies
Galderma begins trading in the Swiss Market Index, joining Switzerland's leading blue chip companies. Also: Galderma's Restylane® Volyme™ demonstrates high effectiveness in Chinese patients; Galderma opens new U.S. and Latin America headquarters in Miami.
Receive all future signals for Galderma & competitors in your briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.